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SHORT REPORT
Gastric bypass surgery has a weight-loss 
independent effect on post-challenge serum 
glucose levels
Dag Hofsø1, Kåre I. Birkeland2,3, Jens J. Holst4, Jens Bollerslev3,5, Rune Sandbu1,6, Jo Røislien1,7 
and Jøran Hjelmesæth1,3*
Abstract 
Background: Gastric bypass surgery seems to have an effect on glucose metabolism beyond what is mediated 
through weight reduction. The magnitude of this effect on fasting and post-challenge glucose levels remains 
unknown.
Results: Morbidly obese subjects without known diabetes performed a 75 g oral glucose tolerance test before and 
after either gastric bypass surgery (n = 64) or an intensive lifestyle intervention programme (n = 55), ClinicalTrials.gov 
identifier NCT00273104. The age-adjusted effects of the therapeutic procedures and percentage weight change on 
fasting and 2-h glucose levels at 1 year were explored using multiple linear regression analysis. Mean (SD) serum fast-
ing and 2-h glucose levels at baseline did not differ between the surgery and lifestyle groups. Weight-loss after surgi-
cal treatment and lifestyle intervention was 30 (8) and 9 (10) % (p < 0.001). At 1 year, fasting and 2-h glucose levels 
were significantly lower in the surgery group than in the lifestyle group, 4.7 (0.4) versus 5.4 (0.7) mmol/l and 3.4 (0.8) 
versus 6.0 (2.4) mmol/l, respectively (both p < 0.001). Gastric bypass and weight-loss had both independent glucose-
lowering effects on 2-h glucose levels [B (95 % CI) 1.4 (0.6–2.3) mmol/l and 0.4 (0.1–0.7) mmol/l per 10 % weight-loss, 
respectively]. Fasting glucose levels were determined by weight change [0.2 (0.1–0.3) mmol/l per 10 % weight-loss] 
and not by type of treatment.
Conclusions: Gastric bypass surgery has a clinically relevant glucose-lowering effect on post-challenge glucose 
levels which is seemingly not mediated through weight-loss alone.
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Background
Reduction in blood glucose levels after gastric bypass 
surgery is related to weight-loss [1, 2]. In addition, a 
weight-loss independent effect of the surgical proce-
dure on glucose metabolism has been hypothesized [2, 
3]. Exaggerated post-prandial insulin secretion observed 
after gastric bypass supports this hypothesis [4–7]. The 
relative effects of weight loss and the surgical proce-
dure per se on fasting and post-challenge glucose levels 
remain, however, unknown.
The aim of the present analysis was to assess the 
effects of weight-loss achieved by gastric bypass sur-
gery and lifestyle intervention on 1 year fasting and 2-h 
glucose levels. Data from oral glucose tolerance tests 
(OGTTs) in the previously published “Morbid Obesity 
treatment, Bariatric surgery versus Intensive Lifestyle 
intervention” (MOBIL) study [1] were analysed. The 
inclusion of a non-surgical weight-loss group made it 
possible to assess the specific effect of the surgical pro-
cedure on fasting and post-challenge glucose levels. To 
our knowledge, this has previously only been addressed 
in a few small studies [8, 9].
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Methods
This is a post hoc analysis of data from the MOBIL study 
[1] conducted at a public tertiary care centre in Nor-
way. The trial included 146 morbidly obese subjects of 
mainly European descent, and aimed to address changes 
in several health outcomes related to obesity after gastric 
bypass surgery or an intensive lifestyle intervention pro-
gramme. A 75  g 2-h OGTT was performed in subjects 
without known diabetes (119 out of 139 completers) at 
the time of inclusion. The present analyses include data 
from these participants. Some of the previously pub-
lished data are included in the present paper as they are 
essential for interpretative purposes [1, 7].
Patients in the surgery group received laparoscopic 
Roux-en-Y gastric bypass, whereas patients who chose 
lifestyle intervention were referred to a rehabilitation 
centre specialising in the care of morbidly obese patients 
(Evjeklinikken A/S, Evje, Norway). The 1  year lifestyle 
programme at the rehabilitation centre aimed to induce 
a weight-loss of at least 10 % and comprised of four stays 
at the centre lasting for either 1 or 4 weeks (total 7 week 
stay).
The regional ethics committee of the Southern Norway 
Regional Health Authority approved the study. The study 
is registered in the ClinicalTrials.gov-registry under the 
unique trial number NCT00273104. Written informed 
consent was provided by all participants.
Data are presented as mean (SD) or number (%). Unad-
justed between-group comparisons were assessed using 
either independent samples t test or the Chi square test. 
Multiple linear regression analyses were used to assess 
the associations between treatment choice and weight 
change on serum glucose levels at 1 year. Due to age dif-
ferences between the groups at baseline and the known 
impact of age on both fasting and 2-h glucose levels, the 
effects of the independent variables were age-adjusted. 
Interaction terms between the two explanatory vari-
ables (group and weight change) were included. Due to a 
standardised residual of 4.81 one case was excluded from 
the correlation and regression analyses including 2-h glu-
cose as the dependent variable. The significance level was 
p < 0.05. Statistical analyses were performed using SPSS 
17.0 (SPSS Inc., Chicago, IL, USA).
Results
Patients in the surgery group were younger [41 (10) ver-
sus 46 (11) years, p = 0.007], heavier [47 (6) versus 43 (5) 
kg/m2, p < 0.001] and had greater weight-loss at one-year 
follow-up [30 (8) versus 9 (10) %, p < 0.001]. The propor-
tion of females did not differ between the surgery and 
lifestyle groups (70 versus 71 %, p = 0.943). Fasting and 
2-h glucose levels at baseline did not differ between the 
surgery and lifestyle groups, 6.1 (1.6) versus 6.0 (1.0) 
mmol/l, p = 0.495 and 7.5 (3.4) versus 7.6 (3.1) mmol/l, 
p = 0.887. In contrast, both fasting and 2-h glucose levels 
were significantly lower in the surgery group than in the 
lifestyle group at 1 year, 4.7 (0.4) versus 5.4 (0.7) mmol/l 
and 3.4 (0.8) versus 6.0 (2.4) mmol/l (both p < 0.001).
The correlations between percentage weight change 
and fasting and 2-h glucose levels 1  year after surgi-
cal and medical treatment are shown in Fig.  1. Weight 
change correlated significantly with fasting glucose lev-
els at 1  year in both groups. Further, the independent 
effects of treatment choice (group) and weight change 
on fasting and 2-h glucose levels were explored in two 
regression models (Table 1). Gastric bypass surgery had 
an independent effect on 2-h glucose levels but not on 
fasting glucose levels at 1  year (Table  1). Nine percent 
Fig. 1 Correlations between percentage weight change and fasting and 2-h glucose levels at 1 year in the surgery and lifestyle groups. **p < 0.01, 
*p < 0.05
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of the variance in 2-h glucose was explained by treat-
ment choice. The mean (95 % CI) glucose-lowering effect 
of surgical treatment on 2-h glucose was 1.4 (0.6–2.3) 
mmol/l. The distance between the group-specific cor-
relation lines in Fig.  1b visualises this effect. Weight 
change per se was independently associated with both 
fasting and 2-h glucose levels and explained 13 and 5 % 
(squared partial correlation) of the variance in the two 
glucose variables, respectively (Table  1). A 10  % weight 
loss was associated with a reduction in fasting glucose of 
approximately 0.2 mmol/l and a reduction in 2-h glucose 
of approximately 0.4 mmol/l (B × 10, Table 1). The asso-
ciations between weight change and fasting and 2-h glu-
cose levels in the two groups did not differ significantly 
(no “group × weight change” interactions, p = 0.371 and 
p  =  0.130, respectively). Age was positively associated 
with both fasting glucose levels and 2-h glucose levels 
and explained 18 and 13 % of the variance in the respec-
tive glucose variables (Table 1). Overall, treatment choice, 
weight change and age explained 46 % (R2 = 0.459) and 
49 % (R2 = 0.491) of the variance in fasting and 2-h glu-
cose levels 1 year after treatment.
Discussion
The main finding of the present study is that gastric 
bypass surgery seems to have an effect on post-challenge 
glucose levels that is partly independent of weight loss, 
while the effect on fasting glucose levels is solely depend-
ent on the degree of weight loss.
These results support the idea that gastric bypass sur-
gery has a direct effect on glucose metabolism beyond 
what is mediated by weight change [3]. However, the 
effect seems to be specific for the post-prandial phase. In 
line with previous studies the procedure does not seem 
to have an independent effect on fasting glucose levels 
[8, 9]. Improved fasting glucose is likely to be caused by 
reduced endogenous hepatic glucose production asso-
ciated with weight-loss [10]. Contrasting our findings, 
changes in post-prandial glucose did not differ signifi-
cantly after 10  % weight-loss induced by either gastric 
bypass or lifestyle intervention [9]. However, the study 
seems inadequately powered (n = 20) for detecting clini-
cally relevant differences in post-prandial glucose levels. 
Supra-physiological post-prandial insulin secretion [4–
7], possibly due to alteration of the gastrointestinal tract 
[11] with rapid glucose absorption [4] and exaggerated 
incretin response [4–6], may possibly explain the weight-
loss independent effect of gastric bypass on 2-h glucose 
levels observed in the present study.
The weight-loss independent glucose lowering effect 
of gastric bypass surgery on 2-h glucose levels might 
be beneficial in subjects with post-prandial hypergly-
caemia. However, the potent effect of gastric bypass 
on post-challenge glycaemia may also increase the 
risk of post-prandial hypoglycaemia. This side effect is 
increasingly recognised to be a potential result of gas-
tric bypass surgery [12]. Age and weight change were 
both significantly and positively associated with 2-h glu-
cose. These findings may suggest that younger subjects 
who experience large weight reduction after surgery 
may have an increased risk of developing post-prandial 
hypoglycaemia.
Most of the patients included in this analysis had glu-
cose levels within the normal or pre-diabetic range, 
meaning that the results cannot be generalised to include 
patients with overt diabetes. Due to the non-randomised 
design of the study we cannot exclude that between-
group differences may have confounded our interpreta-
tion of the data. However, no differences in glucose levels 
at baseline were observed. Moreover, statistical adjust-
ments for differences in age between the two groups were 
performed in order to minimise any confounding.
Conclusions
The strong post-challenge glucose lowering effect of gas-
tric bypass surgery on 2-h glucose is partly independent 
of weight-loss. This finding supports the presence of gas-
tric bypass specific glucose regulatory mechanisms.
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Table 1 Multiple linear regression analyses with  treatment choice, weight change and  age as  explanatory variables 
and fasting and 2-h serum glucose levels at 1 year as outcome variables
Group: surgery = 0, lifestyle = 1
Fasting serum glucose 2-h serum glucose
B (95 % CI) Squared partial  
correlation
P value B (95 % CI) Squared partial  
correlation
P value
Group 0.118 (−0.177 to 0.414) 0.005 0.429 1.443 (0.585–2.301) 0.089 0.001
Weight change (%) 0.022 (0.012–0.033) 0.132 <0.001 0.038 (0.007–0.068) 0.049 0.017
Age (years) 0.022 (0.013–0.031) 0.177 <0.001 0.054 (0.028–0.079) 0.132 <0.001
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